Please note: This is for information only.
Refer to local guidelines for treatment recommendations
- Voriconazole is a synthetic antifungal agent belonging to the azole group. It inhibits the enzyme 14-alpha lanosterol and thereby disrupts the synthesis of ergosterol in the fungal cell membrane.
- Available in oral and intravenous formulations.
- Oral bioavailability is high (~96%) and tissue distribution is extensive.
- Elimination is by hepatic metabolism; no dose adjustment is required in patients with renal impairment, however, IV preparation should be avoided in patients with renal impairment as accumulation of the vehicle may occur
- Usual Adult dose: 400 mg every 12 hours for 2 doses then 200 mg every 12 hours (assuming body weight > 40 Kg).
- Numerous drug interactions.
- Microbiology advice – restricted agent.
- Consultant approval as part of the haematology neutropenic sepsis protocol.
Active against most strains of:
- Candida spp.
- Aspergillus spp.
- Cryptococcus neoformans (inc. fluconazole-resistant strains)
- Dimorphic pathogens such as Blastomyces dermatitidis, Coccidioides immitis and Histoplasma capsulatum
- Fusarium spp.
- Scedosporium spp.
- Penicillium marneffei
- Not active against most strains of:
- Zygomycetes (Mucor, Rhizpus and Absidia).